Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.

Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.

The Echelon-3 study seemed doomed, but it just read out positively for overall survival.

Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?

New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.

BeiGene has a strong presence at this year’s AACR, which features several notable duels.